0.3497

2.73% 0.0093

X 4 Pharmaceuticals Inc (XFOR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$0.3404

Aprire:

$0.34

Volume 24 ore:

985.67K

Relative Volume:

0.44

Capitalizzazione di mercato:

$58.05M

Reddito:

Utile/perdita netta:

$-101.17M

Rapporto P/E:

-0.3363

EPS:

-1.04

Flusso di cassa netto:

$-96.57M

1 W Prestazione:

-14.71%

1M Prestazione:

-29.50%

6M Prestazione:

-61.00%

1 anno Prestazione:

-56.35%

Intervallo 1D:

$0.3336

$0.35

Intervallo di 1 settimana:

$0.3149

$0.41

Portata 52W:

$0.2612

$1.60

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Nome

X 4 Pharmaceuticals Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

857-529-8300

Indirizzo

61 NORTH BEACON STREET, BOSTON, MA

Dipendente

143

Cinguettio

@x4pharma

Prossima data di guadagno

2024-11-13

Ultimi documenti SEC

XFOR's Discussions on Twitter

Confronta XFOR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
XFOR	0.3497	58.05M	0	-101.17M	-96.57M	-1.04
VRTX	449.72	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	747.06	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	595.00	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	246.52	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	108.14	24.89B	3.30B	-501.07M	1.03B	11.54

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-08-30	Ripresa	B. Riley Securities	Buy
2022-12-22	Iniziato	Cantor Fitzgerald	Overweight
2022-12-12	Iniziato	Piper Sandler	Overweight
2019-12-23	Iniziato	Oppenheimer	Outperform
2019-12-18	Iniziato	ROTH Capital	Buy
2019-12-09	Aggiornamento	Citigroup	Neutral → Buy
2019-12-05	Iniziato	B. Riley FBR	Buy
2019-06-07	Iniziato	Stifel	Buy
2019-06-05	Iniziato	Cowen	Outperform

Mostra tutto

X 4 Pharmaceuticals Inc Borsa (XFOR) Ultime notizie

04:15 AM

Atenolol Global Market 2024 – Top Manufacturers, Latest Trends, Future Prospects And Outlook By 2033 - WhaTech

04:15 AM

01:17 AM

Benzodiazepine Drugs Market Overview: Industry Insights, Demand Trends, Competitive Landscape, and Key Inno... - WhaTech

Nov 20, 2024

Nov 19, 2024

Chronic Pain Market Set for Steady Growth with 4% CAGR Driven by Drugs and Devices | Future Market Insights, Inc. - GlobeNewswire

Nov 19, 2024

Nov 18, 2024

10 Biggest Biotechnology Companies - Investopedia

Nov 18, 2024

Layoff Tracker: Gilead Sciences Will Lay Off 104 Employees at California HQ - BioSpace

Nov 18, 2024

HC Wainwright Predicts Lower Earnings for X4 Pharmaceuticals - MarketBeat

Nov 18, 2024

Nov 15, 2024

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

RFK Jr vow to purge FDA sets up collision with Big Pharma - Reuters.com

Nov 15, 2024

Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary - Fast Company

Nov 15, 2024

Nov 14, 2024

Earnings call: X4 Pharmaceuticals reports progress in CN treatment By Investing.com - Investing.com Nigeria

Nov 14, 2024

CANbridge Pharmaceuticals Inc. (HKG:1228) Not Doing Enough For Some Investors As Its Shares Slump 28% - Simply Wall St

Nov 14, 2024

XFOR: Positive Results for Phase 2 Trial of Mavorixafor in Chronic Neutropenia… - Zacks Small Cap Research

Nov 14, 2024

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline - Quantisnow

Nov 14, 2024

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference - Yahoo Finance

Nov 14, 2024